Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 9 | 2010 | 2481 | 0.410 |
Why?
|
Raloxifene Hydrochloride | 1 | 2004 | 16 | 0.240 |
Why?
|
Estrogen Receptor Modulators | 1 | 2004 | 38 | 0.240 |
Why?
|
Aromatase Inhibitors | 1 | 2005 | 75 | 0.240 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2004 | 60 | 0.230 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2004 | 253 | 0.210 |
Why?
|
Self Concept | 3 | 2010 | 157 | 0.200 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2001 | 98 | 0.180 |
Why?
|
Guilt | 3 | 2010 | 15 | 0.180 |
Why?
|
Spirituality | 3 | 2010 | 48 | 0.160 |
Why?
|
Adaptation, Psychological | 4 | 2010 | 462 | 0.140 |
Why?
|
Taxoids | 2 | 2005 | 68 | 0.120 |
Why?
|
Motivation | 2 | 2006 | 314 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2005 | 1069 | 0.090 |
Why?
|
Quality of Life | 4 | 2010 | 1932 | 0.090 |
Why?
|
Sick Role | 2 | 2006 | 31 | 0.080 |
Why?
|
Survivors | 1 | 2010 | 345 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2005 | 353 | 0.070 |
Why?
|
Public Sector | 1 | 2006 | 13 | 0.070 |
Why?
|
Attitude | 1 | 2007 | 119 | 0.070 |
Why?
|
Breast Diseases | 1 | 2006 | 34 | 0.070 |
Why?
|
Social Adjustment | 1 | 2006 | 84 | 0.060 |
Why?
|
Mastectomy, Segmental | 1 | 2005 | 27 | 0.060 |
Why?
|
Nitriles | 1 | 2005 | 146 | 0.060 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2005 | 102 | 0.060 |
Why?
|
Triazoles | 1 | 2005 | 138 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2005 | 1213 | 0.060 |
Why?
|
Social Support | 1 | 2006 | 344 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2004 | 263 | 0.060 |
Why?
|
Depression | 2 | 2010 | 1226 | 0.060 |
Why?
|
Tamoxifen | 1 | 2005 | 363 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 730 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2003 | 1672 | 0.050 |
Why?
|
Personality Inventory | 3 | 2010 | 166 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2006 | 420 | 0.050 |
Why?
|
Genes, abl | 1 | 2001 | 7 | 0.050 |
Why?
|
Genes, cdc | 1 | 2001 | 25 | 0.050 |
Why?
|
Imatinib Mesylate | 1 | 2001 | 45 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2005 | 1681 | 0.050 |
Why?
|
Benzamides | 1 | 2001 | 107 | 0.050 |
Why?
|
Research Design | 1 | 2004 | 686 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2005 | 714 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 1089 | 0.040 |
Why?
|
Survival Rate | 1 | 2005 | 1996 | 0.040 |
Why?
|
Interferon-alpha | 1 | 2001 | 221 | 0.040 |
Why?
|
Piperazines | 1 | 2001 | 231 | 0.040 |
Why?
|
Risk Assessment | 2 | 2006 | 3334 | 0.040 |
Why?
|
Iron | 1 | 2001 | 261 | 0.040 |
Why?
|
Pyrimidines | 1 | 2001 | 374 | 0.040 |
Why?
|
Female | 9 | 2010 | 65494 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2005 | 1681 | 0.040 |
Why?
|
Middle Aged | 6 | 2010 | 26002 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2003 | 1012 | 0.040 |
Why?
|
Hematopoietic Stem Cells | 1 | 2001 | 533 | 0.040 |
Why?
|
Incidence | 1 | 2004 | 3050 | 0.040 |
Why?
|
Macrophages, Peritoneal | 1 | 1997 | 38 | 0.030 |
Why?
|
Macrophage Activation | 1 | 1997 | 61 | 0.030 |
Why?
|
Amphotericin B | 1 | 1997 | 90 | 0.030 |
Why?
|
Candida albicans | 1 | 1997 | 76 | 0.030 |
Why?
|
Hospitals, Public | 2 | 2006 | 38 | 0.030 |
Why?
|
Humans | 11 | 2010 | 123184 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2005 | 5050 | 0.030 |
Why?
|
Adult | 5 | 2007 | 29065 | 0.030 |
Why?
|
Apoptosis | 1 | 2001 | 1781 | 0.030 |
Why?
|
Antifungal Agents | 1 | 1997 | 293 | 0.030 |
Why?
|
Surveys and Questionnaires | 3 | 2010 | 3670 | 0.030 |
Why?
|
Aged | 3 | 2006 | 19088 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2001 | 1197 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2006 | 868 | 0.030 |
Why?
|
Neoadjuvant Therapy | 2 | 2005 | 321 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2005 | 12129 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2005 | 1012 | 0.020 |
Why?
|
United States | 1 | 2004 | 10632 | 0.020 |
Why?
|
Texas | 2 | 2006 | 3560 | 0.020 |
Why?
|
Uncompensated Care | 1 | 2006 | 10 | 0.020 |
Why?
|
Hospitals, General | 1 | 2006 | 24 | 0.020 |
Why?
|
Health Surveys | 1 | 2006 | 241 | 0.020 |
Why?
|
Attitude to Health | 1 | 2006 | 260 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 2006 | 229 | 0.010 |
Why?
|
Genes, erbB-2 | 1 | 2003 | 38 | 0.010 |
Why?
|
Mastectomy | 1 | 2003 | 63 | 0.010 |
Why?
|
Trastuzumab | 1 | 2003 | 138 | 0.010 |
Why?
|
Poverty | 1 | 2006 | 419 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2006 | 530 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2005 | 1416 | 0.010 |
Why?
|
Psychometrics | 1 | 2005 | 667 | 0.010 |
Why?
|
HL-60 Cells | 1 | 2001 | 31 | 0.010 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2001 | 68 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2003 | 650 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2006 | 826 | 0.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2003 | 497 | 0.010 |
Why?
|
Anxiety | 1 | 2006 | 956 | 0.010 |
Why?
|
Kinetics | 1 | 2001 | 1313 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2005 | 2847 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2006 | 3379 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1997 | 153 | 0.010 |
Why?
|
Drug Carriers | 1 | 1997 | 98 | 0.010 |
Why?
|
Liposomes | 1 | 1997 | 168 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2006 | 6376 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2001 | 1907 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2001 | 2528 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1997 | 3046 | 0.010 |
Why?
|
Adolescent | 1 | 2006 | 19118 | 0.000 |
Why?
|
Male | 1 | 2006 | 60083 | 0.000 |
Why?
|
Mice | 1 | 1997 | 17486 | 0.000 |
Why?
|
Animals | 1 | 1997 | 33714 | 0.000 |
Why?
|